Randomized trial evaluating the role of weight loss in overweight and obese men with early stage prostate Cancer on active surveillance: Rationale and design of the Prostate Cancer Active Lifestyle Study (PALS)

Active surveillance (AS) is increasingly used to monitor patients with low-risk prostate cancer; however, approximately 50% of AS patients experience disease reclassification requiring definitive treatment and little is known about patient characteristics that modify the risk of reclassification. Obesity may be one of the major contributing factors.The Prostate Cancer Active Lifestyle Study (PALS) is a clinical trial evaluating the impact of weight loss among overweight/obese (Body Mass Index (BMI)  ≥ 25 kg/m2) men with clinically localized prostate cancer on AS.

Source: Contemporary Clinical Trials - April 15, 2019 Category: Radiology Authors: Jeannette M. Schenk, Marian L. Neuhouser, Sarah J. Beatty, Matthew VanDoren, Daniel W. Lin, Michael Porter, John L. Gore, Roman Gulati, Stephen R. Plymate, Jonathan L. Wright Source Type: research